Related Experiment Video
Updated: Feb 10, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Safety and Immunogenicity of Pneumococcal Conjugate Vaccine in Preterm Infants: A Meta-Analysis
Kai Duan1, Jin Guo2, Ping Lei3
1Wuhan Institute of Biological Products, Co., Ltd., Wuhan, China. duankai63@163.com.
Insights
Pneumococcal conjugate vaccines (PCVs) are safe and well-tolerated in preterm infants. While immune responses may be slightly lower in preterm infants, PCV-7 demonstrates optimal immunogenicity, even in very-low-birth-weight infants.
Area of Science:
- Pediatric Vaccinology
- Immunology
- Neonatal Health
Background:
- Preterm infants represent a vulnerable population requiring specific vaccination strategies.
- Pneumococcal conjugate vaccines (PCVs) are crucial for preventing invasive pneumococcal disease.
- Assessing the safety and immunogenicity of PCVs in preterm infants is essential for public health.
Purpose of the Study:
- To evaluate the safety and immunogenicity of pneumococcal conjugate vaccines (PCVs) in preterm infants.
- To compare vaccine responses between preterm and full-term infants.
- To determine the efficacy of PCVs in very-low-birth-weight (VLBW) infants.
Main Methods:
- A systematic review and random-effects meta-analysis was conducted.
- Data were extracted and analyzed in accordance with the PRISM statement.
- Included studies involved infants immunized with PCV-7, PCV-10, or PCV-13.
Main Results:
- PCVs demonstrated a favorable safety profile in preterm infants, with risk ratios for local and systemic reactions comparable to full-term infants.
- Genomic mean concentrations (GMCs) for several pneumococcal serotypes were lower in preterm infants compared to full-term infants, particularly for serotype 19F.
- Immune responses, including seroconversion rates, were generally comparable between preterm and full-term infants after primary vaccination, and PCV-7 showed robust immunogenicity in VLBW infants.
Conclusions:
- Preterm infants exhibit good tolerance to PCV-7, PCV-10, and PCV-13.
- PCV-7 vaccination elicits an optimal immune response in preterm infants, including those with very-low-birth-weight.
- These findings support the use of PCVs in preterm infant populations to ensure adequate protection against pneumococcal disease.
Objective:
To assess the safety and immunogenicity of pneumococcal conjugate vaccine (PCVs) in preterm infants.
Methods:
In accordance with the PRISM (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement (as of May 2015), a meta-analysis was conducted to evaluate the safety and immunogenicity of PCVs in preterm infants.
Results:
Ten thousand nine hundred sixty full-term infants and 2131 preterm infants with 344 preterm infants of <2500 g birth weight [low-birth weight (LBW)] were included, and all the subjects were immunized with either PCV-7, PCV-10 or PCV-13 in this random-effects meta-analysis. For safety, the range of risk ratio (RRs) for local reaction was from 0.88 to 1.02 and from 0.94 to 1.24 for systematic reaction respectively. For immunogenicity, either post-primary or booster vaccination with PCV-7, PCV-10 or PCV-13, genomic mean concentration (GMC) of serotypes 4, 6B, 9 V, 19F and 23F was always less in preterm infants than in full-term infants, in which huge comparison of GMC was found in serotype 19F(SMD = -0.393, 95%CI:-0.612 ~ 0.175). After primary vaccination, the combined risk ratio (RRs) of immune response against seven common serotypes and additional serotype 1 was approximated to 1.00 with narrow 95 % confidence interval (CI) between preterm infants and full-term infants, and at least 91 % sero-conversion of two additional serotypes, 5 and 7F in two cohorts was observed. Furthermore, between very-low-birth-weight (VLBW) infants of <1500 g and 1501 ~ 2500 g, overall RRs of immune response to PCV-7 administration was 0.98 (95%CI: 0.96 ~ 1.00).
Conclusions:
Preterm infants have a great tolerance to PCV-7, PCV-10 or PCV-13 vaccination. PCV-7 could elicit optimal immune response post vaccination in preterm infants, even in VLBW infants.
Related Concept Videos
Survey Safety
Conjugation
Vaccinations
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Conjugated Proteins
Directing Effect of Substituents: meta-Directing Groups

